Table 2 Associations of continuous allometric anthropometric indices with breast cancer risk

Overall

9011

0.984 (0.961–1.007)

0.162

1.013 (0.990–1.036)

0.276

1.074 (1.049–1.098)

< 0.001

MP baseline

Pre-MP

2178

0.988 (0.941–1.038)

0.643

1.028 (0.982–1.075)

0.239

0.980 (0.932–1.030)

0.422

Post-MP

5268

0.971 (0.942-1.000)

0.051

1.011 (0.981–1.041)

0.490

1.117 (1.085–1.150)

< 0.001

p _{heterogeneity}

0.535

0.543

< 0.001

Age diagnosis

<55 years

1968

1.006 (0.956–1.059)

0.817

1.026 (0.979–1.076)

0.285

0.966 (0.917–1.019)

0.206

≥55 years

7043

0.976 (0.951–1.002)

0.067

1.006 (0.981–1.032)

0.630

1.104 (1.076–1.132)

< 0.001

p _{heterogeneity}

0.299

0.476

< 0.001

ERPR status

ER + PR+

3101

0.971 (0.933–1.010)

0.141

1.016 (0.978–1.056)

0.409

1.122 (1.080–1.165)

< 0.001

ER + PR-

726

0.894 (0.822–0.971)

0.008

0.981 (0.905–1.063)

0.644

0.998 (0.917–1.086)

0.956

ER-PR-

759

0.906 (0.835–0.983)

0.018

1.028 (0.951–1.112)

0.487

0.996 (0.919–1.081)

0.933

p _{heterogeneity}

0.108

0.682

0.004

ER+/-PR-

1485

0.900 (0.849–0.954)

< 0.001

1.006 (0.951–1.064)

0.842

0.997 (0.940–1.057)

0.924

p _{ER+/−PR− vs. ER+PR+}

0.037

0.763

< 0.001

HER2 status

ER + PR + HER2+

288

1.042 (0.918–1.183)

0.526

0.972 (0.860–1.098)

0.647

1.206 (1.073–1.356)

0.002

ER + PR + HER2-

1690

0.981 (0.929–1.035)

0.474

1.016 (0.965–1.071)

0.542

1.148 (1.091–1.207)

< 0.001

p _{heterogeneity}

0.390

0.511

0.449

ER+/-PR-HER2+

298

0.934 (0.822–1.062)

0.297

0.970 (0.858–1.096)

0.624

1.045 (0.921–1.185)

0.493

ER+/-PR-HER2-

626

0.904 (0.826–0.989)

0.027

1.017 (0.932–1.109)

0.703

1.013 (0.926–1.108)

0.778

p _{heterogeneity}

0.680

0.536

0.693

TNBC

314

0.927 (0.817–1.051)

0.238

1.046 (0.925–1.182)

0.473

0.993 (0.874–1.127)

0.908